X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

Content Team by Content Team
14th February 2022
in Packaging & Logistic, Press Statements
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

DoKaSch Temperature Solutions achieved technical approvals for its “Opticooler” active containers with Japan Airlines (JAL) and All Nippon Airways (ANA). Thus, on all flights operated by Japan’s two largest airlines, forwarders can now use the fast available and highly reliable temperature-controlled packaging solution. In addition to a dedicated Japanese subsidiary and a new service station in Tokyo-Narita, the approval of both Japanese major carriers further strengthens DoKaSch Temperature Solutions’ network in the Asia-Pacific region. Given the highest availability on the market and resilience of the Opticooler packaging solution, customers have enhanced options to operate safe and reliable supply chains for temperature-sensitive goods to and from Asia.

The technical approvals allow the Opticooler to be used in the cargo holds of the two airlines’ fleets. Forwarders and pharmaceutical manufacturers in Japan and worldwide are thus benefitting from increasing leasing options for temperature-controlled packaging solutions and can utilize the well-developed international route networks of both carriers. JAL’s and ANA’s schedules connect Japan with Europe, North America, Southeast Asia as well as Australia. The option of using Opticoolers on these routes is hence opening important accesses to the Japanese and worldwide pharma sector. At Narita International Airport for example, both carriers operate a hub where half of Japan’s total pharmaceutical trade is being handled. Freight forwarders also profit from the efficient and capable range of wide body aircrafts of both carriers, which allows the Opticoolers to always be deployed with optimal and reliable flying platforms.

The technical approval follows the opening of a new service station of DoKaSch in 2021 at Tokyo-Narita Airport. The new depot is ready to meet any demand for RKN and RAP Opticooler at any time and immediately. The German company has also established the dedicated Japanese subsidiary DoKaSch Temperature Solutions K.K. with an office in Tokyo in 2021. In addition to its high availability, the Opticooler is an extremely reliable, temperature-controlled packaging-solution. Without depending on dry ice or other refrigerants, the active container can both cool and heat thanks to a self-supporting electrical power generator and full climate control. They maintain the desired temperature level, e.g. between 2° and 8° Celsius at all times and regardless of external climatic and infrastructural conditions. This makes them the ideal solution for the safe transport of highly sensitive and valuable pharmaceutical products that must always be protected from temperature fluctuations.

“The demand for temperature-sensitive goods is increasing in Japan as well as in whole Asia. In addition to reliability and safety, fast availability at any quantity is also crucial, to step up with this trend. Combined with our new Japanese service station directly at the gateway of our new partners Japan Airlines and All Nippon Airways, we can excellently provide these key capabilities to our customers in the Asia-Pacific region,” says Kazuyoshi Kakizawa, Head of DoKaSch Temperature Solutions K.K..

Andreas Seitz, Managing Director of DoKaSch Temperature Solutions, adds: “The new technical approvals by Japan Airlines and All Nippon Airways are a major step for our growth strategy in Asia. Thanks to the new cooperation, we are further expanding our established and dense global network. With its market leading reliability as well as availability, our Opticooler packaging solution will thereby become available to even more customers in Asia as well as worldwide.”

About DoKaSch Temperature Solutions:

DoKaSch is a family-owned supplier of loading equipment to the global aviation industry. With almost 30 years of experience, DoKaSch has acquired a far-reaching set of skills to develop, manufacture, maintain and market all sorts of unit load devices (ULD) for the transportation of goods and luggage in aircrafts around the world.

At DoKaSch Temperature Solutions, we focus on renting out our Opticooler, an inhouse developed air-conditioned temperature-controlled container, to international airlines. The Opticooler is designed to transport and safeguard high value, temperature sensitive cargo such as pharmaceuticals on intercontinental flights. Our Opticooler-Containers ensure that throughout all climate zones the pharmaceutical cargo reaches its destination safe and undamaged.

The “Made in Germany” DoKaSch Opticooler work autonomously with batteries. It is valued for its exceptional reliability and performance at any climatic and weather situation and keeps cargo very accurately within the 2-8°C or 15-25°C range.

Many well-known pharmaceutical companies have been relying on the Opticooler for years as a way to deliver their vital medicines safely, reliably and undamaged to patients around the world.

Previous Post

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

Next Post

Envirotainer introduces the RAP for the future - part of the Releye series

Related Posts

Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
Future Trends Shaping
Packaging & Logistic

Future Trends Shaping Pharma Supply Chain and Logistics

30th July 2025
GSK and Hengrui Pharma
Drug Development

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

29th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Next Post
Envirotainer introduces the RAP for the future - part of the Releye series

Envirotainer introduces the RAP for the future - part of the Releye series

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In